跳转至内容
Merck
CN
所有图片(1)

主要文件

AP504P

Sigma-Aldrich

山羊抗人IgGγ链抗体,HRP偶联,吸附物种

Chemicon®, from goat

登录查看公司和协议定价


About This Item

UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.46

生物来源

goat

质量水平

偶联物

peroxidase conjugate

抗体形式

affinity purified immunoglobulin

抗体产品类型

secondary antibodies

克隆

polyclonal

种属反应性

human

制造商/商品名称

Chemicon®

技术

ELISA: suitable

运输

wet ice

靶向翻译后修饰

unmodified

一般描述

IgG是人血清中含量最丰富的蛋白之一。IgG 对我们抵抗微生物很重要,而B淋巴细胞产生的分子是我们适应性免疫应答的一部分。IgG 分子具有两个独立的功能;与引起反应的病原体结合,以及募集其他细胞和分子来破坏抗原。IgG 池的变异性是通过体细胞重组产生的。

特异性

与人IgG的重链反应。吸收用于人IgM、IgD和IgA。

应用

使用经验证可用于ELISA的山羊抗人IgGγ链抗体HRP偶联物,吸附种属检测人IgGγ链。

外形

通过亲和色谱法对与琼脂糖共价连接的合并人IgG进行纯化。液体溶于50%甘油/50%PBS,pH值7.4。没有添加防腐剂。

法律信息

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

未找到合适的产品?  

试试我们的产品选型工具.

储存分类代码

10 - Combustible liquids

WGK

WGK 2


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Lisa M Smith et al.
Journal of virology, 95(23), e0088221-e0088221 (2021-09-23)
Human and simian immunodeficiency virus (HIV and SIV) infections establish lifelong reservoirs of cells harboring an integrated proviral genome. Genome editing CRISPR-associated Cas9 nucleases, combined with SIV-specific guiding RNA (gRNA) molecules, inactivate integrated provirus DNA in vitro and in animal
Mark J Bailey et al.
Nature communications, 9(1), 4560-4560 (2018-11-06)
Zika virus is a mosquito-borne flavivirus closely related to dengue virus that can cause severe disease in humans, including microcephaly in newborns and Guillain-Barré syndrome in adults. Specific treatments and vaccines for Zika virus are not currently available. Here, we
Hyesun Jang et al.
Heliyon, 9(7), e17958-e17958 (2023-07-24)
A growing number of studies indicate that coronavirus disease 2019 (COVID-19) is associated with inflammatory sequelae, but molecular signatures governing the normal versus pathologic convalescence process have not been well-delineated. Here, we characterized global immune and proteome responses in matched
Ryan T Bushey et al.
Molecular cancer therapeutics, 22(6), 778-789 (2023-03-31)
Development of novel therapeutic antibodies that not only kill tumor cells but modulate the adaptive immune response has the potential to produce long term anticancer immunity and a durable clinical response. We previously reported the discovery of anti-complement factor H

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门